217 related articles for article (PubMed ID: 32982437)
1. The Significance of CXCL1 and CXCL8 as Well as Their Specific Receptors in Colorectal Cancer.
Łukaszewicz-Zając M; Pączek S; Mroczko P; Kulczyńska-Przybik A
Cancer Manag Res; 2020; 12():8435-8443. PubMed ID: 32982437
[TBL] [Abstract][Full Text] [Related]
2. The Significance of CXCL1 and CXCR1 as Potential Biomarkers of Colorectal Cancer.
Łukaszewicz-Zając M; Zajkowska M; Pączek S; Kulczyńska-Przybik A; Safiejko K; Juchimiuk M; Kozłowski L; Mroczko B
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509572
[TBL] [Abstract][Full Text] [Related]
3. Loss of SMAD4 Promotes Colorectal Cancer Progression by Recruiting Tumor-Associated Neutrophils via the CXCL1/8-CXCR2 Axis.
Ogawa R; Yamamoto T; Hirai H; Hanada K; Kiyasu Y; Nishikawa G; Mizuno R; Inamoto S; Itatani Y; Sakai Y; Kawada K
Clin Cancer Res; 2019 May; 25(9):2887-2899. PubMed ID: 30705034
[TBL] [Abstract][Full Text] [Related]
4. The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue.
Oladipo O; Conlon S; O'Grady A; Purcell C; Wilson C; Maxwell PJ; Johnston PG; Stevenson M; Kay EW; Wilson RH; Waugh DJ
Br J Cancer; 2011 Feb; 104(3):480-7. PubMed ID: 21285972
[TBL] [Abstract][Full Text] [Related]
5. Associations of C-X-C motif chemokine ligands 1/2/8/13/14 with clinicopathological features and survival profile in patients with colorectal cancer.
Luo X; Tai J; Zhao Y; Zhao P; Sun D; Wang L
Oncol Lett; 2022 Oct; 24(4):348. PubMed ID: 36072008
[TBL] [Abstract][Full Text] [Related]
6. Chemokine (C-X-C motif) ligand 1 is associated with tumor progression and poor prognosis in patients with colorectal cancer.
Zhuo C; Wu X; Li J; Hu D; Jian J; Chen C; Zheng X; Yang C
Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29784873
[TBL] [Abstract][Full Text] [Related]
7. The CXCL8-CXCR1/2 pathways in cancer.
Liu Q; Li A; Tian Y; Wu JD; Liu Y; Li T; Chen Y; Han X; Wu K
Cytokine Growth Factor Rev; 2016 Oct; 31():61-71. PubMed ID: 27578214
[TBL] [Abstract][Full Text] [Related]
8. Chemokines-What Is Their Role in Colorectal Cancer?
Pączek S; Łukaszewicz-Zając M; Mroczko B
Cancer Control; 2020; 27(1):1073274820903384. PubMed ID: 32103675
[TBL] [Abstract][Full Text] [Related]
9. The Clinicopathological Significance of the CXCR2 Ligands, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8 in Gastric Cancer.
Yamamoto Y; Kuroda K; Sera T; Sugimoto A; Kushiyama S; Nishimura S; Togano S; Okuno T; Yoshii M; Tamura T; Toyokawa T; Tanaka H; Muguruma K; Ohira M; Yashiro M
Anticancer Res; 2019 Dec; 39(12):6645-6652. PubMed ID: 31810929
[TBL] [Abstract][Full Text] [Related]
10. An inter-correlation among chemokine (C-X-C motif) ligand (CXCL) 1, CXCL2 and CXCL8, and their diversified potential as biomarkers for tumor features and survival profiles in non-small cell lung cancer patients.
Gu L; Yao Y; Chen Z
Transl Cancer Res; 2021 Feb; 10(2):748-758. PubMed ID: 35116406
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of
Rasool M; Natesan Pushparaj P; Karim S
Saudi J Biol Sci; 2021 Nov; 28(11):6045-6049. PubMed ID: 34764737
[TBL] [Abstract][Full Text] [Related]
12. Serum CXCL8 and Its Specific Receptor (CXCR2) in Gastric Cancer.
Pawluczuk E; Łukaszewicz-Zając M; Gryko M; Kulczyńska-Przybik A; Mroczko B
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680333
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the molecular interactions of interleukin-8 (CXCL8), growth related oncogen alpha (CXCL1) and a non-peptide antagonist (SB 225002) with the human CXCR2.
Catusse J; Liotard A; Loillier B; Pruneau D; Paquet JL
Biochem Pharmacol; 2003 Mar; 65(5):813-21. PubMed ID: 12628493
[TBL] [Abstract][Full Text] [Related]
14. Complementary action of CXCL1 and CXCL8 in pathogenesis of gastric carcinoma.
Chen X; Jin R; Chen R; Huang Z
Int J Clin Exp Pathol; 2018; 11(2):1036-1045. PubMed ID: 31938199
[TBL] [Abstract][Full Text] [Related]
15. CCL20 and CXCL8 synergize to promote progression and poor survival outcome in patients with colorectal cancer by collaborative induction of the epithelial-mesenchymal transition.
Cheng XS; Li YF; Tan J; Sun B; Xiao YC; Fang XB; Zhang XF; Li Q; Dong JH; Li M; Qian HH; Yin ZF; Yang ZB
Cancer Lett; 2014 Jun; 348(1-2):77-87. PubMed ID: 24657657
[TBL] [Abstract][Full Text] [Related]
16. CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer.
Cabrero-de Las Heras S; Martínez-Balibrea E
World J Gastroenterol; 2018 Nov; 24(42):4738-4749. PubMed ID: 30479461
[TBL] [Abstract][Full Text] [Related]
17. Expression of chemokines and chemokine receptors in human colon cancer.
Erreni M; Bianchi P; Laghi L; Mirolo M; Fabbri M; Locati M; Mantovani A; Allavena P
Methods Enzymol; 2009; 460():105-21. PubMed ID: 19446722
[TBL] [Abstract][Full Text] [Related]
18. Expression and migratory analysis of 5 human uveal melanoma cell lines for CXCL12, CXCL8, CXCL1, and HGF.
Di Cesare S; Marshall JC; Logan P; Antecka E; Faingold D; Maloney SC; Burnier MN
J Carcinog; 2007 Jan; 6():2. PubMed ID: 17261188
[TBL] [Abstract][Full Text] [Related]
19. Pleiotropic effects of CXC chemokines in gastric carcinoma: differences in CXCL8 and CXCL1 expression between diffuse and intestinal types of gastric carcinoma.
Eck M; Schmausser B; Scheller K; Brändlein S; Müller-Hermelink HK
Clin Exp Immunol; 2003 Dec; 134(3):508-15. PubMed ID: 14632759
[TBL] [Abstract][Full Text] [Related]
20. The prognostic significance of CXCL1 hypersecretion by human colorectal cancer epithelia and myofibroblasts.
le Rolle AF; Chiu TK; Fara M; Shia J; Zeng Z; Weiser MR; Paty PB; Chiu VK
J Transl Med; 2015 Jun; 13():199. PubMed ID: 26104296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
